[Haze or calcific band keratopathy after crosslinking treatment?].
Wollensak
G
G
Hammer
T
T
Herrmann
C I A
CI
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D002114:Calcinosis / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D002130:Calcium Phosphates / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use; D003316:Corneal Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D004492:Edetic Acid / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D012256:Riboflavin / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D002130:Calcium Phosphates; D002614:Chelating Agents; D017319:Photosensitizing Agents; C020243:calcium phosphate; D004492:Edetic Acid; D012256:Riboflavin
Clin Exp Ophthalmol. 2007 Aug;35(6):580-2
17760642
Ophthalmology. 1997 Mar;104(3):375-80
9082259
Eur J Ophthalmol. 1991 Oct-Dec;1(4):173-80
1821211
Pathol Oncol Res. 2002;8(1):41-6
11994762
Ophthalmologe. 2008 May;105(5):485-7
17661057